Plasma phenytoin concentration in epileptic patients with adequate seizure control in a North-Eastern tertiary care hospital in India

Arky J. Langstieh; Julie B. Wahlang; Baiakmenlang Synmon; Chayna Sarkar; Namit  Ray; Krishnamoorthi R.

doi:10.18203/2319-2003.ijbcp20261116

Authors

Arky J. Langstieh Department of Pharmacology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India
Julie B. Wahlang Department of Pharmacology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India
Baiakmenlang Synmon Department of Neurology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India
Chayna Sarkar Department of Pharmacology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India
Namit Ray Department of Pharmacology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India
Krishnamoorthi R. Department of Pharmacology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20261116

Keywords:

Anti-epileptics, Epilepsy, HPLC, Phenytoin

Abstract

Background: In this study, estimation of plasma phenytoin level was done on epileptic patients with adequate seizure control. Since, no such study reporting on phenytoin estimation on seizure-free period in the north-eastern part of India was undertaken; hence rationale of adequate seizure control with phenytoin is yet to be ascertained. This retrospective study is being done to obtain a satisfactory clinical outcome with minimal adverse effects in our setting regarding the target plasma level of phenytoin.

Methods: The patients from the Neurology Department were enrolled for this study. Blood samples were taken and the plasma extracted was used for the phenytoin estimation using HPLC.

Results: Results showed that the majority of the study population exhibited total plasma phenytoin levels within the recommended therapeutic range (10-20 μg/ml).

Conclusions: The study findings showed that patients with adequate seizure control exhibited plasma phenytoin concentration within the recommended therapeutic level, which is the safe level of the drug in blood. However, some variations in the plasma phenytoin level are suggestive of the inter-individual differences in pharmacokinetics after phenytoin therapy. Hence, monitoring of phenytoin treatment is necessary to ensure dosage delivery is at therapeutic levels and to avoid any untoward toxicity.

Author Biography

Baiakmenlang Synmon, Department of Neurology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India

Associate professor, Department of Neurology, NEIGRIHMS

References

Van Diessen E, Zweiphenning WJ, Jansen FE, Stam CJ, Braun KP, Otte WM. Brain network organization in focal epilepsy: a systematic review and meta-analysis. PloS One. 2014;9:114606.

Dixit PK, Mittal S, Chauhan B. Screening models used for anti-epileptic activity and various herbal sources beneficial in epilepsy: a review. Eur J Pharm Med Res. 2015;2:843-55.

Luna-Munguia H, Starski P, Chen W, Gliske S, Stacey WC. Control of in vivo ictogenesis via endogenous synaptic pathways. Sci Rep. 2017;7:1311.

Garg D. Specific considerations for epilepsy in India. Current Med. 2020;18:105-10.

Shah RA, Shah RA. Development and validation of RP-HPLC method for phenytoin sodium and phenobarbitone in bulk and pharmaceutical dosage form. Int J Pharm Pharm Sci. 2017;9:224.

Adil M, Farhat S, Rather MY. Therapeutic drug monitoring of phenytoin using high performance liquid chromatography in a tertiary care hospital of Kashmir, India. Int J Basic Clin Pharmacol. 2019;8:995.

Wu MF, Lim WH. Phenytoin: a guide to therapeutic drug monitoring. Proc Singap Healthc. 2013;22:198-202.

Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24:1-10.

Khedr A, Moustafa M, Abdel-Naim AB, Alahdal A, Mosli H. High-performance liquid chromatographic method for determination of phenytoin in rabbits receiving sildenafil. Anal Chem Insight. 2008;3:61-7.

Krumholz A. To drive or not to drive: the 3-month seizure-free interval for people with epilepsy. InMayo Clinic Proceedings. 2003;78:817-8.

Flores J, Alexander S, Babayeva M. A novel HPLC method for determination of phenytoin in human plasma. J Pharm Res Int. 2018;22:343.

Singu BS, Morrison H, Irengeya L, Verbeeck RK. Therapeutic drug monitoring of phenytoin and valproic acid in critically ill patients at Windhoek Central Hospital, Namibia. Afr J Lab Med. 2022;11:1628.

Mandal NK, Rauniar GP, Rai DS, Pradhan B, Poudel P, Sapkota N. Therapeutic drug monitoring of antiepileptic drugs at a tertiary care hospital of eastern Nepal. Kathmandu Univ Med J. 2019;17:160-5.

Lertsinudom S, Chaiyakum A, Tuntapakul S, Sawanyawisuth K, Tiamkao S, Tiamkao S. Integrated Epilepsy Research Group. Therapeutic drug monitoring in epilepsy clinic: a multi-disciplinary approach. Neurol Int. 2014;6:5620.

Panagariya A, Sharma B, Dubey P, Satija V, Rathore M. Prevalence, demographic profile and psychological aspects of epilepsy in North-Western India: a community-based observational study. Ann Neurosci. 2018;25:177-86.

Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52:5-10.

Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. "Therapeutic" serum concentration of phenytoin: the influence of seizure type. J Neurol Neurosurg Psych. 1984;47:231-4.

Ahmed R. High-Performance Liquid Chromatography (HPLC): Principles, Applications, Versatality, Efficiency, Innovation and Comparative Analysis in Modern Analytical Chemistry and In Pharmaceutical Sciences. Clin. Invest. 2024;14:524-35.

Morikawa G, Fukami K, Moriiwa Y, Okazawa K, Yanagida A. Evaluation of the clinical and quantitative performance of a practical HPLC-UV platform for in-hospital routine therapeutic drug monitoring of multiple drugs. J Pharm Health Care Sci. 2023;9:29.